Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key ...

Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...

Topline results announced today show gains in KCCQ and peak oxygen consumption—the full dataset is coming soon.

Robert Blum and Fady Malik, M.D., Ph.D, have been with Cytokinetics since its inception nearly three decades ago. | ...

The ACACIA-HCM trial met both primary endpoints, potentially opening treatment to a new population of heart disease patients ...

By Sneha S K May 5 (Reuters) - Cytokinetics said on Tuesday its experimental heart disease drug significantly improved symptoms of a genetic heart condition in a late-stage trial, sending its shares ...

Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and ...

HCM causes the heart muscle to abnormally thicken, making it harder for the heart to pump blood effectively. According to the ...

Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...

Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern TimeSOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- ...